Dermatitis: Clinical Trials

1347 completed, 243 unknown, 204 recruiting, 147 terminated. 569 Not applicable, 518 Phase 2, 328 Phase 3, 296 Phase 1, 180 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	569	Completed 326, Unknown 88, Recruiting 50, Terminated 35, Not yet recruiting 26, Withdrawn 26, Active not recruiting 12, Enrolling by invitation 6
Phase 2	518	Completed 331, Terminated 53, Recruiting 36, Unknown 36, Active not recruiting 29, Withdrawn 18, Not yet recruiting 12, Enrolling by invitation 3
Phase 3	328	Completed 217, Recruiting 24, Unknown 23, Active not recruiting 17, Not yet recruiting 15, Terminated 15, Withdrawn 14, Enrolling by invitation 3
Phase 1	296	Completed 193, Terminated 26, Recruiting 25, Unknown 20, Withdrawn 13, Not yet recruiting 11, Active not recruiting 7, Enrolling by invitation 1
Phase 4	180	Completed 118, Unknown 16, Terminated 15, Not yet recruiting 12, Recruiting 8, Active not recruiting 6, Withdrawn 5
Early Phase 1	27	Completed 12, Unknown 4, Terminated 3, Withdrawn 3, Enrolling by invitation 2, Recruiting 2, Not yet recruiting 1

Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients Skin Cleanser Combination No.1 - Atopic Dermatitis	Phase 4	Not yet recruiting	Boston Children's Hospital	100	2031-01-01	2026-03-10
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis Ivermectin Pill - Atopic Dermatitis	Phase 2	Withdrawn	Stanford University		2030-12-01	2024-12-02
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Site specific standard of care comparison - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis		Withdrawn	Massachusetts General Hospital		2030-01-01	2026-01-16
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis EC-18, Placebo EC-18 - Atopic Dermatitis	Phase 2	Not yet recruiting	Enzychem Lifesciences Corporation	150	2027-05-01	2026-08-28
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis	Phase 3	Not yet recruiting	Pfizer	90	2027-05-01	2026-09-16
Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome) Benralizumab 30 MG/ML [Fasenra], Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride - DRESS Syndrome	Phase 2	Not yet recruiting	University Hospital, Lille	96	2027-01-06	2026-05-15
Educational Eczema Video Intervention in-clinic video intervention, at home video intervention - Eczema	Not applicable	Withdrawn	Boston Children's Hospital		2027-01-01	2026-10-19
Opzelura Experience Study ruxolitinib, ruxolitinib and an Eczema Action Plan - Atopic Dermatitis	Phase 4	Not yet recruiting	Wake Forest University Health Sciences	50	2026-12-01	2026-09-04
Localized Aeroallergen Exposure in Atopic Dermatitis Localized grass pollen allergen exposure, Localized placebo exposure - Atopic Dermatitis	Not applicable	Not yet recruiting	Fraunhofer-Institute of Toxicology and Experimental Medicine	15	2026-12-01	2026-11-05
Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation Dupilumab coformulated with berahyaluronidase alfa, Dupilumab - Dermatitis Atopic	Phase 3	Not yet recruiting	Sanofi	150	2026-11-30	2026-11-05
Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis Digital App Mindfulness Meditation, Mindfulness Meditation Sheet - Atopic Dermatitis, Eczema	Not applicable	Recruiting	Weill Medical College of Cornell University	40	2026-11-15	2026-10-23
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis baricitinib - Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome	Phase 1	Recruiting	National Institute of Allergy and Infectious Diseases (NIAID)	20	2026-11-15	2026-11-10
AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes Lebrikizumab-lbkz - Atopic Dermatitis	Phase 4	Not yet recruiting	Forefront Dermatology S.C	250	2026-11-11	2026-10-02
Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis Investigational cream - Atopic Dermatitis, Psoriasis	Not applicable	Not yet recruiting	Brainfarma Industria Química e Farmacêutica S/A	42	2026-11-06	2026-11-05
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants GLR2053 Tablets, Placebo - Atopic Dermatitis	Phase 1	Not yet recruiting	Gan & Lee Pharmaceuticals.	124	2026-11-05	2026-11-06
Determinants of Radiation Dermatitis in Head and Neck Cancer Patients Receiving Preventive Photobiomodulation Preventive photobiomodulation, External beam radiotherapy, Functional, quality-of-life and photographic assessments - Head and Neck Neoplasms, Radiodermatitis		Not yet recruiting	Hopital Forcilles	150	2026-11-02	2026-10-28
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis	Phase 3	Not yet recruiting	Almirall, S.A.	230	2026-11-01	2026-10-14
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis HSK60002 tablets, HSK60002 Placebo - Dermatitis Atopic	Phase 1	Not yet recruiting	Haisco Pharmaceutical Group Co., Ltd.	60	2026-11-01	2026-11-06
A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis NOR-101, Placebo - Atopic Dermatitis (AD)	Phase 1	Not yet recruiting	North Immunology Inc.	96	2026-11-01	2026-10-29
Artificial Intelligence Powered Digital Education Based on the Neuman Systems Model for Breast Cancer Patients Receiving Radiotherap Neuman-Based AI-Supported Digital Education Program, Standard Care (in control arm) - Breast Cancer, Radiodermatitis	Not applicable	Not yet recruiting	Ataturk University	38	2026-11-01	2026-10-28

Showing 20 of 2231. Sign in to see all of them.

Narrower conditions

Dermatitis, Atopic (1521)  ·  Eczema (455)  ·  Radiodermatitis (126)  ·  Psoriasis (110)  ·  Pruritus (94)  ·  Skin Diseases (88)  ·  Asthma (72)  ·  Breast Neoplasms (70)  ·  Hypersensitivity (70)  ·  Dermatitis, Contact (57)  ·  Dermatitis, Seborrheic (56)  ·  Dermatitis, Allergic Contact (49)  ·  Food Hypersensitivity (45)  ·  Hand-Foot Syndrome (43)

Broader conditions

Skin and Connective Tissue Diseases (2230)  ·  Skin Diseases (2143)  ·  Skin Diseases, Eczematous (1866)  ·  Immune System Diseases (1669)  ·  Hypersensitivity (1600)  ·  Hypersensitivity, Immediate (1545)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1538)  ·  Genetic Diseases, Inborn (1527)  ·  Skin Diseases, Genetic (1511)  ·  Pathological Conditions, Signs and Symptoms (225)  ·  Skin Diseases, Papulosquamous (170)  ·  Signs and Symptoms (155)  ·  Wounds and Injuries (134)  ·  Neoplasms (125)

Interventions

dupilumab (94)  ·  pimecrolimus (42)  ·  abrocitinib (33)  ·  Tacrolimus (28)  ·  lebrikizumab (28)  ·  Adrenal Cortex Hormones (26)  ·  upadacitinib (26)  ·  tralokinumab (21)  ·  crisaborole (20)  ·  Ointments (18)  ·  baricitinib (17)  ·  Blood Specimen Collection (16)  ·  Cyclosporine (16)  ·  Standard of Care (15)  ·  nemolizumab (15)

Sponsors

Pfizer (59)  ·  Sanofi (42)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (41)  ·  LEO Pharma (40)  ·  AbbVie (31)  ·  Novartis Pharmaceuticals (30)  ·  Regeneron Pharmaceuticals (30)  ·  Eli Lilly and Company (29)  ·  Incyte Corporation (21)  ·  GlaxoSmithKline (20)  ·  Bayer (19)  ·  Northwestern University (19)  ·  Astellas Pharma Inc (17)  ·  Galderma R&D (16)  ·  Novartis (16)

Countries

United States (838)  ·  Germany (274)  ·  Canada (261)  ·  China (229)  ·  France (177)  ·  Poland (174)  ·  United Kingdom (154)  ·  Spain (141)  ·  Japan (128)  ·  Australia (117)  ·  Italy (107)  ·  South Korea (95)  ·  Netherlands (86)  ·  Taiwan (83)  ·  Czechia (81)

Top investigators

Amy Paller, MD (9)  ·  Robert Bissonnette, MD (9)  ·  Joseph Fowler, MD (7)

Results publications

PMID 39588375, PMID 33826132, PMID 42162528, PMID 34406619, PMID 36255569, PMID 36723913, PMID 38896380, PMID 40993471, PMID 33165005, PMID 39104653, PMID 40028832, PMID 25006719, PMID 31066001, PMID 33453450, PMID 34142350, PMID 35061234, PMID 35342978, PMID 35567671, PMID 35636689, PMID 36749121, PMID 36808602, PMID 38777187, PMID 40555305, PMID 41118053, PMID 31407311, PMID 31424712, PMID 33658996, PMID 33954933, PMID 33982267, PMID 34037993, PMID 34275122, PMID 34688290, PMID 34726270, PMID 34743361, PMID 34897582, PMID 35305260, PMID 35462428, PMID 35714786, PMID 35763326, PMID 36152216, PMID 36525340, PMID 36754548, PMID 37043227, PMID 37247226, PMID 37949351, PMID 37988255, PMID 39008191, PMID 39110139, PMID 39441580, PMID 40085349

NIH funding

2018 (34), 2023 (21), 2019 (15), 2017 (13), 2025 (13), 2014 (8), 2016 (7), 2008 (6), 2015 (5), 2009 (3), P30CA012197 (3), R21AR062357 (2), 2004 (1), K24HD069408 (1), P01GM095467 (1)